Ensuring diversity of volunteers in clinical trials is a matter of equity and good science. People respond to medicines and vaccines differently and we believe all patients should have the opportunity to receive the latest breakthrough treatments. This starts with equitable access to clinical trials.

We can only make progress if we understand our starting point, so we published a landmark retrospective analysis in *Contemporary Clinical Trials* of the ethnic, racial, age and gender diversity of our clinical trials initiated in the US between 2011 and 2020 to serve as an important industry benchmark and to measure our future progress.

Looking at overall participation against US census data revealed close gaps

But looking at participation in individual trials showed where there is work to be done

**Vaccine trials** had a lower percentage of Black or African American and Hispanic or Latino participants, and a higher percentage of Asian, White, and Non-Hispanic White participants.

**Clinical pharmacology trials** had higher percentages of Black or African American and Hispanic or Latino participants.

**Therapeutic trials** had a larger percentage of White participants.

Over 60% of trials in Cardiology, Hematology, Endocrinology and Nephrology had representation above census levels of Black or African American and Hispanic or Latino populations.

Methodology: We analyzed 213 clinical trials conducted in the US between 2011 and 2020. Trials covered all 5 of our therapeutic areas: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease and Vaccines, along with our legacy Neuroscience portfolio.